



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/600,645	06/23/2003	John M. Wozney	08702.0048-03000	6135
22852 75	22852 7590 08/11/2005		EXAMINER	
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413			LI, RUIXIANG	
			ART UNIT	PAPER NUMBER
			1646	···

DATE MAILED: 08/11/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Office Antique Comment	10/600,645	WOZNEY ET AL.			
Office Action Summary	Examiner	Art Unit			
	Ruixiang Li	1646			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1) Responsive to communication(s) filed on 27 May 2005.					
2a) This action is FINAL . 2b) ☐ This	s action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) Claim(s) 1,4,6,8,10-13,19 and 31 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) 1,4,6,8,10-13 and 19 is/are allowed. 6) Claim(s) 31 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
9) The specification is objected to by the Examiner.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s)					
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary (Paper No(s)/Mail Da				
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date <u>03/17/2005</u> .					

Application/Control Number: 10/600,645

Art Unit: 1646

Page 2

DETAILED ACTION

Status of Application, Amendments, and/or Claims

Applicants' amendment filed on 05/27/2005 has been entered in full. Claims 2, 3, 5, 9,

14-18, 20-23, and 32-52 have been canceled. Claims 1, 4, 6, 8, 10, 11, and 13 have

been amended. Claims 1, 4, 6, 8, 10-13, 19, and 31 are pending and under

consideration.

The text of those sections of Title 35, U.S. Code not included in this action can be found

in a prior Office Action.

Withdrawn Objections and/or Rejections

The objection to the disclosure as set forth at page 2 of the previous Office Action

(Paper No. 20050124, mailed on 01/28/2005) has been withdrawn in view of the

amended specification.

All the rejections set forth in the previous Office Action (Paper No. 20050124, mailed on

01/28/2005) that are not reiterated in this action have been withdrawn in view of

amended claims, canceled claims, and Applicants' argument.

Application/Control Number: 10/600,645 Page 3

Art Unit: 1646

Information Disclosure Statement

The information disclosure statement filed on 03/17/2005 has been considered by the

Examiner and a signed copy has been attached to this office action.

Claims Rejections under 35 U.S.C. 112, 1st paragraph, Enablement

The rejection of claim 31 under 35 U.S.C. 112, first paragraph, as set forth at page 7 of

the previous Office Action (Paper No. 20050124, mailed on 01/28/2005), is maintained.

Applicants have amended the specification to recite the date of the deposit, the

complete name and address of the depository, and the accession number of the

deposited material. However, Applicants have not amended the claim to recite the

specific deposit information for the DNA sequence of CFK1-23a clone. It is suggested

that the claim be amended to read: "An isolated DNA molecule comprising the DNA

sequence of SEQ ID NO: 1" or "An isolated DNA molecule comprising the DNA

sequence deposited under ATCC accession number 69378".

Claims Rejections under 35 U.S.C. 112, 2nd paragraph

Claim 31 is indefinite because it recites "CFK1-23a". Such a term is determined

arbitrarily without a definitive structure. Others in the field may isolate the same protein

and give an entirely different name, as is the case here. As acknowledged in Applicants'

response (the middle of page 10) filed on 05/27/2005, the CFK1-23a protein is also

known in the art as BMPR-1A, ALK3, and BRK1. Thus, claiming biochemical molecules

Art Unit: 1646

by a particular name given to the protein by various workers in the field fails to distinctly

claim what the protein is. Applicants should particularly point out and distinctly claim the

CFK1-23a protein by claiming characteristics associated with the protein (e.g., a

sequence identifier). This is a new ground of rejection.

Conclusion

Claims 1, 4, 6, 8, 10-13, and 19 are allowed.

Advisory Information

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875.

The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00

pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Anthony Caputa, can be reached on (571) 272-0829. The fax number for the

organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published

applications may be obtained from either Private PAIR or Public PAIR. Status

information for unpublished applications is available through Private PAIR only. For

more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

Application/Control Number: 10/600,645 Page 5

Art Unit: 1646

have questions on access to the Private PAIR system, please contact the Electronic

Business Center (EBC) at the toll-free phone number 866-217-9197.

Ruixiang Li, Ph.D.

Examiner

August 4, 2005